首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2058258

抗精神病藥物市場：依疾病、藥物、治療類別、通路和地區分類。

Antipsychotic Drugs Market, By Disease, By Drug, By Therapeutic Class,By Distribution Channel, By Geography

出版日期: 2026年05月08日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年抗精神病藥物市場規模估計為194億美元，預計2033年將達到322.4億美元。預計2026年至2033年，該市場將以7.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	194億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.50%	2033年市場規模預測：	322.4億美元

思覺失調症的推動，市場正在穩步成長。

抗精神病藥物在治療嚴重精神疾病中發揮著至關重要的作用，它們透過調節神經傳導物質（尤其是多巴胺和血清素路徑）的活性，抑制幻覺、妄想和情緒波動等症狀。該市場包括第一代（典型）抗精神病藥物以及第二代和第三代（非典型）抗精神病藥物，其中非典型藥物由於療效更佳、副作用更少而越來越受到青睞。

藥物研發領域的技術進步，特別是長效注射劑（LAI）製劑和新型非典型分子藥物的出現，正在透過提高患者依從性和降低復發率來改變治療效果。此外，監管機構對創新治療方法的支持力度不斷加大，以及對個人化精神科治療的日益重視，進一步增強了全球市場的成長前景。

市場動態

抗精神病藥物市場正經歷強勁成長，這主要受臨床、人口和監管因素的共同推動。其中一個關鍵促進因素是全球精神疾病盛行率的不斷上升。光是思覺失調症就影響著全球超過2000萬人，而雙相情感障礙及相關精神病性障礙仍然是導致長期殘疾的主要原因，從而持續推高了對抗精神病療法的需求。

另一個主要的成長要素是老年人口的增加。老年人更容易患上與失智症相關的精神病和其他神經精神疾病，這些疾病需要抗精神病藥物治療。人們對精神健康治療的認知不斷提高，以及社會對精神疾病污名化的減少，尤其是在新興經濟體，也促進了診斷和治療率的提高。

此外，製劑的持續創新也推動了市場發展。緩釋注射型抗精神病藥物因其遵守用藥依從性並降低住院率而廣泛應用。同時，新型非典型抗精神病藥物和緩釋製劑的推出，也改善了治療效果，並為臨床醫師拓展了治療選擇。

然而，副作用、患者用藥依從性差以及保險對新治療方法的報銷限制等挑戰仍然在一定程度上限制市場成長。儘管存在這些挑戰，但醫療保健支出的成長、心理健康計畫的擴展以及強大的開發平臺預計將推動市場長期持續擴張。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司亮點、服務組合、重大發展、財務績效和策略等參數，對主要抗精神病藥物市場參與者進行了概況介紹。
透過利用本報告中的見解，行銷負責人和經營團隊將能夠就未來的服務創新、市場擴張和策略合作夥伴關係做出明智的決策。
抗精神病藥物市場報告的目標受群眾外包括投資者、服務供應商、製藥公司、監管機構和金融分析師等各類相關人員。
相關人員可以利用系統分析框架和策略矩陣來評估抗精神病藥物市場，從而獲得巨大利益。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第9章競爭情勢

公司簡介
- H. Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkermes
- Bristol-Myers Squibb Company

第10章

參考
調查方法

簡介目錄

Product Code: CMI1196

Antipsychotic Drugs Market is estimated to be valued at USD 19.4 Bn in 2026 and is expected to reach USD 32.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 19.4 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.50%	2033 Value Projection:	USD 32.24 Bn

The market is experiencing steady expansion driven by the rising global burden of mental health disorders such as schizophrenia, bipolar disorder, and psychosis, alongside increasing awareness, diagnosis rates, and acceptance of long-term pharmacological treatment strategies.

Antipsychotic drugs play a critical role in managing severe psychiatric conditions by regulating neurotransmitter activity, particularly dopamine and serotonin pathways, to control symptoms such as hallucinations, delusions, and mood instability. The market includes both first-generation (typical) and second- and third-generation (atypical) antipsychotics, with atypical drugs increasingly preferred due to improved efficacy and reduced side-effect profiles.

Technological advancements in drug development, particularly long-acting injectable (LAI) formulations and novel atypical molecules, are transforming treatment outcomes by improving patient adherence and reducing relapse rates. Additionally, growing regulatory support for innovative therapies and increasing focus on personalized psychiatric care are further strengthening market growth prospects across global regions.

Market Dynamics

The Antipsychotic Drugs Market is witnessing robust growth due to multiple converging clinical, demographic, and regulatory factors. A key driver is the increasing prevalence of mental health disorders worldwide. Schizophrenia alone affects over 20 million people globally, while bipolar disorder and related psychotic conditions continue to contribute significantly to long-term disability, creating sustained demand for antipsychotic therapies.

Another major growth factor is the rising geriatric population, which is more susceptible to dementia-related psychosis and other neuropsychiatric conditions requiring antipsychotic intervention. Expanding awareness and reduced stigma around mental health treatment are also contributing to higher diagnosis and treatment rates, especially in emerging economies.

The market is further supported by continuous innovation in drug formulations. Long-acting injectable antipsychotics are gaining strong adoption due to improved medication adherence and reduced hospitalization rates. Additionally, the introduction of newer atypical antipsychotics and extended-release formulations is enhancing treatment outcomes and expanding therapeutic options for clinicians.

However, challenges such as adverse side effects, patient non-adherence, and reimbursement limitations for newer therapies continue to restrain market growth to some extent. Despite these challenges, increasing healthcare expenditure, expansion of mental health programs, and strong regulatory pipelines are expected to sustain long-term market expansion.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Antipsychotic Drugs Marketbased on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
Key companies covered as a part of this study include H. Lundbeck A/S; Otsuka Pharmaceutical Co., Ltd.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; AbbVie, Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Sumitomo Pharma Co., Ltd.; Alkermes; Bristol-Myers Squibb Company
Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
The Antipsychotic Drugs Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Antipsychotic Drugs Market

Market Segmentation

By Disease (Revenue, USD Bn, 2026-2033)
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
By Drug (Revenue, USD Bn, 2026-2033)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
By Therapeutic Class (Revenue, USD Bn, 2026-2033)
- First Generation
- Second Generation
- Third Generation
By Distribution Channel (Revenue, USD Bn, 2026-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region (Revenue, USD Bn, 2026-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkermes
- Bristol-Myers Squibb Company

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Disease
- Market Snippet, By Drug
- Market Snippet, By Therapeutic Class
- Market Snippet, By Distribution Channel
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
Technological Advancement
Regulatory Scenario

4. Global Antipsychotic Drugs Market, By Disease, 2021- 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Unipolar Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Antipsychotic Drugs Market, By Drug, 2021 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Paliperidone Palmitate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Antipsychotic Drugs Market, By Therapeutic Class 2021- 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
First Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Second Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Third Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Antipsychotic Drugs Market, By Distribution Channel 2021- 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Antipsychotic Drugs Market, By Region, 2021- 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
North America
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of APAC
Middle East
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - South Africa
  - Central Africa
  - North Africa

9. Competitive Landscape

Company Profiles
- H. Lundbeck A/S
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Janssen Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Dr. Reddy's Laboratories Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sumitomo Pharma Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Alkermes
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies